CytRx Posts Decline in Q4 Loss Amid Lower Costs; Despite Lack of Cash, RNAi Spin Out Expected Soon | GenomeWeb

CytRx released this week its financial results for the fourth quarter of 2005, posting a drop in losses on lower expenses.

The company also said that the spinout of its RNAi-based drug-development efforts into a new company is expected to be completed "in the coming months," but noted in a filing with the US Securities and Exchange Commission that it still has not secured the money necessary to do so.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.